Sarcoma Patient Advocacy Global Network (spagn)

What Sarcoma Patient Advocacy Global Network (spagn) does

SPAGN (Sarcoma Patient Advocacy Global Network) is a nonprofit patient advocacy organization registered as a German eingetragener Verein (e.V./Assoc.) with its headquarters at Untergasse 36, D-61200 Wölfersheim, Germany. Originally established as Sarcoma Patients EuroNet, the organization formally rebranded as a global entity in 2022. SPAGN operates as an umbrella network uniting more than 60 national sarcoma patient advocacy organizations across 5 continents, serving individuals affected by sarcoma, caregivers, clinicians, and researchers. Its core activities are organized around four pillars: information dissemination (Voices of Sarcoma blog, newsletters, lay summaries of medical consensus), advocacy capacity building (working groups, expert-patient roundtables, Sarcoma Awareness Month campaigns reaching 30+ patient groups in 10+ languages), research collaboration (consensus initiatives, the Global Sarcoma Diagnosis Pathway Survey with 1,800+ respondents in 49 countries), and policy influence (white papers such as the Italian Sarcoma White Paper presented at the Chamber of Deputies in Rome).

The organization does not develop or sell commercial technology products; its infrastructure consists of web-based platforms for educational content, member coordination, and event management. SPAGN's primary revenue streams are recurring membership fees from national patient advocacy organizations and conference/event revenue from registrations tied to the SPAGN Annual Conference (held in Dublin 2023, Washington D.C. 2025, and Stockholm 2026) and the New Horizons GIST event. The organization is member-funded and has not disclosed any equity funding rounds or external investment.

SPAGN's go-to-market is community-led and event-driven: growth is driven by recruiting national advocacy groups, deepening engagement through conferences and webinars, and maintaining formal collaboration programs with major oncology societies (CTOS, ESMO, EMSOS, ASCO) plus institutional partners such as the U.S. National Cancer Institute, Karolinska University Hospital, FDA, NIH, and the WECAN Foundation. Awards programs (Advocacy in Action Awards, Paola Gonzato Memory Award, Lifetime Achievement Awards) function as member engagement and recognition mechanisms rather than commercial activities.

Name

Sarcoma Patient Advocacy Global Network (spagn)

Legal name

Sarcoma Patient Advocacy Global Network e.V./Assoc.

Website

https://sarcoma-patients.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

SPAGN is a German-registered nonprofit patient advocacy network uniting 60+ national sarcoma advocacy organizations across 5 continents, delivering education, advocacy, and research collaboration for sarcoma patients, caregivers, clinicians, and researchers worldwide.

Ownership category

akta.pro rank

Headquarters

HQ city

Wölfersheim

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: SPAGN generates revenue through membership fees from patient advocacy organizations. Member groups join SPAGN to strengthen their collective voice and access resources, networking, and international collaboration opportunities.
2. Conference and Event Revenue: SPAGN organizes annual conferences including the SPAGN Annual Conference and New Horizons GIST. These events generate revenue through registration fees and attract participants including patients, advocates, healthcare professionals, and industry partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Core offering

SPAGN operates as a global membership network uniting national sarcoma patient advocacy organizations to strengthen the collective international patient voice. It delivers its offering through annual conferences, webinars, expert-patient roundtables, working groups, educational publications, awareness campaigns, and policy advocacy initiatives such as the Global Sarcoma Diagnosis Pathway Survey. Core deliverables are advocacy capacity building, evidence-based research, awareness raising, and policy influence for the global sarcoma community.

Product overview

SPAGN (Sarcoma Patient Advocacy Global Network) is a patient advocacy organization, not a technology product company. It operates as a global network connecting national sarcoma patient advocacy organizations with approximately 60+ member groups across 5 continents. The organization provides advocacy services, organizes conferences and events, publishes educational resources, and facilitates research collaboration—not commercial software products. Core activities include the annual SPAGN Conference (held in locations including Dublin 2023, Washington D.C. 2025, Stockholm 2026), the New Horizons GIST conference, the Voices of Sarcoma blog, Sarcoma Awareness Month campaigns, expert-patient roundtables, working groups, and the publication of lay summaries of medical consensus documents.

Differentiator

Problem solved

Functional benefit

Products and services

• SPAGN Membership for National Sarcoma Patient Advocacy Organizations Recurring membership offering for national sarcoma patient advocacy organizations that join SPAGN to access international collaboration, advocacy capacity building, networking with peer organizations across 5 continents, and unified representation in global sarcoma policy and research forums.
• SPAGN Annual Conference Flagship annual in-person and hybrid conference bringing together patient advocates, sarcoma patients, clinicians, researchers, and industry partners. The 15th edition was held in Washington D.C. in 2025 (over 120 participants from nearly 30 countries, co-hosted with the U.S. National Cancer Institute) and the 16th edition was held at Karolinska University Hospital in Stockholm in 2026.
• New Horizons GIST Conference Dedicated annual conference focused on Gastrointestinal Stromal Tumors (GIST), convening patient advocates, clinicians, researchers, and industry partners to share advances in GIST treatment, research, and patient support.

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• CTOS (Connective Tissue Oncology Society)coreStrategic or Co-development PartnerSPAGN has an established CTOS-SPAGN Collaboration for global patient involvement in sarcoma care. SPAGN participates annually in CTOS meetings with dedicated patient advocacy sessions, including the Patient Advocacy @ CTOS program and CTOS Poster Wall.
• ESMO (European Society for Medical Oncology)coreStrategic or Co-development PartnerSPAGN presents patient-driven research findings at ESMO Annual Meetings, including results from the Global Sarcoma Diagnosis Pathway Survey, engaging healthcare professionals with evidence grounded in real patient experience.
• EMSOS (European Musculoskeletal Oncology Society)coreStrategic or Co-development PartnerSPAGN participates in EMSOS annual congresses, which bring together musculoskeletal oncology specialists. The 2026 congress in Portugal featured patient testimonials and highlighted the importance of patient voice in care and research.
• ASCO (American Society of Clinical Oncology)coreStrategic or Co-development PartnerSPAGN participates in ASCO Annual Meetings to present sarcoma research updates and engage with the global oncology community on patient-centered perspectives.
• FDA (U.S. Food and Drug Administration)minorStrategic or Co-development PartnerSPAGN promotes the CURE ID platform, developed by FDA in collaboration with NIH, which enables sarcoma patients to share treatment experiences to inform future research and clinical trials.
• NIH (U.S. National Institutes of Health)minorStrategic or Co-development PartnerNIH collaborated with FDA and patient organizations to develop CURE ID platform for rare cancer patients, including sarcoma, to share treatment experiences and contribute to drug repurposing research.
• WECAN FoundationminorStrategic or Co-development PartnerSPAGN promotes the WECAN Patient Experience Data (PED) online course launching on World Cancer Day, designed to help patient organizations build skills in generating and using patient experience data for healthcare decisions.
• U.S. National Cancer InstitutecoreStrategic or Co-development PartnerCo-host of the 15th SPAGN Annual Conference 2025 in Washington D.C., marking SPAGN's first conference outside Europe and demonstrating strong institutional collaboration.
• Karolinska University HospitalcoreStrategic or Co-development PartnerHost of the 16th SPAGN Annual Conference 2026 in Stockholm. Karolinska has implemented Whole Genome Sequencing as routine clinical practice for suspected sarcoma based on research demonstrating diagnostic benefits.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Myeloma Patients Europe (MPE): European umbrella of myeloma patient organizations, with growing global activities. Comparable in mission, member-network model, and focus on a rare hematologic cancer, with similar conferences, working groups, and policy engagement.
• Global Lung Cancer Coalition (GLCC): International coalition of lung cancer patient organizations. Comparable as a cancer-specific global umbrella running awareness campaigns, member networking, and joint advocacy outputs across multiple countries.
• International Brain Tumour Alliance (IBTA): Global alliance of brain tumour patient advocacy groups. Closely comparable as another rare-cancer-specific global advocacy network that convenes conferences, publishes resources, and links national patient organizations internationally.
• International Myeloma Foundation (IMF): Global myeloma patient and research advocacy organization with international chapters and conferences. Comparable as a cancer-focused umbrella combining patient education, advocacy, and research engagement across geographies.
• NORD (National Organization for Rare Disorders): US-based umbrella organization for rare disease patient advocacy groups. Directly comparable to SPAGN as a membership-driven advocacy network coordinating national groups across disease areas, with conferences, research funding, and policy advocacy functions.
• WECAN (Workgroup of European Cancer Patient Advocacy Networks): European umbrella coordinating cancer-specific patient advocacy networks. Comparable as SPAGN is explicitly a WECAN partner and WECAN functions as a peer meta-network organizing capacity-building for cancer advocacy umbrellas like SPAGN.
• EURORDIS – Rare Diseases Europe: European umbrella of rare disease patient organizations, founded and headquartered in Europe. Mirrors SPAGN's structure of aggregating national advocacy groups, running awareness campaigns, and engaging regulators and policymakers at the EU level.
• Lymphoma Coalition: Global network of lymphoma patient organizations. Closely comparable in being a cancer-specific global advocacy umbrella running patient surveys, member services, and annual meetings across multiple countries.

Broad incumbents

• Cancer Support Community: Large international nonprofit providing social and emotional support for people impacted by cancer. Comparable as a global cancer patient-facing organization, though broader in scope than SPAGN's rare-disease focus.

Regional players

• Rare Cancers Australia: Australian advocacy organization for patients with rare and less common cancers. Comparable in mission (rare cancer patient support, advocacy, and information) but operates primarily in the Australian market rather than globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/sarcomapatients
• YouTubeyoutube.com/channel/UCHuAgubL-RhBQtNfFcWb9uQ
• Facebookfacebook.com/Sarcoma-Patients-EuroNet-SPAEN-150381014994411
• LinkedInlinkedin.com/company/sarcoma-patients
• Instagraminstagram.com/sarcoma_patients

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sarcoma Patient Advocacy Global Network (spagn)